NCT07134192Recruiting
Fluorescence-Guided Optimization of Sarcoma Margins
Source: ClinicalTrials.gov · Last updated 1 Jul 2026
Brief summary (registry, in English)
This is a Danish national multicenter prospective cohort study to evaluate if fluorescence-guided surgery (FGS) using indocyanine green (ICG) can reduce the rate of positive margins following sarcoma resection.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 90 (estimated)
- First submitted
- 13 Aug 2025
- Start date
- 1 Sept 2025
- Primary completion date
- 1 Feb 2028
- Lead sponsor
- University of Aarhus
- Diseases
- Sarcoma
- NCT number
- NCT07134192
What you commit to
- Study type: Interventional
- Planned participants: 90
- From 1 Sept 2025 to the primary completion date, 1 Feb 2028
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- History of allergic reaction to iodine-containing pharmaceuticals
Lab values
- End-stage renal disease or eGFR \<15
Other
- Patient decision
- Lack of capacity
- Inoperability
Who the study is looking for
- Biopsy verified intermediate-to-high grade sarcoma of theextremity or trunk wall
- Age\>18 years old
- Tumor operable
- Curative intent at time of surgery
- Consent of patient
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Aarhus University Hospital Coordinator of this site? Confirm its status | Aarhus N | Denmark | Recruiting |
| Rigshospitalet Coordinator of this site? Confirm its status | Copenhagen | Denmark | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.